Long-term Safety Study of BHV-3500 (Vazegepant) for the Acute Treatment of Migraine

Condition:   Acute Treatment of Migraine Intervention:   Drug: Vazegepant (BHV-3500) Sponsor:   Biohaven Pharmaceuticals, Inc. Not yet recruiting

Source: ClinicalTrials.gov - May 29, 2020 Category: Research Source Type: clinical trials